AIM-quoted Sareum Holdings Plc (LON:SAR) is taking to the stage at one of Europe’s leading biopartnering and investment conferences this week.
The specialist cancer drug discovery firm’s chief executive, Tim Mitchell, will be giving two presentations at BioTrinity 2017 in London.
The first – which is later this afternoon (Tuesday) at the Novotel hotel in Hammersmith – will showcase Sareum and its lead programmes, while the second is tomorrow and will see Mitchell present to a panel of investors.
BioTrinity is the largest conference of its type in the UK and attracts life sciences investors from around the world as well as big pharma executives and emerging R&D companies, Sareum said.
“BioTrinity offers us ideal opportunities to present our latest developments to both investors and potential licence partners,” said CEO Mithcell.